about
Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis.Fifty shades of yellow: a review of the xanthodermatoses.No evidence that human papillomavirus is responsible for the aggressive nature of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma.Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire.The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease.Performing surgery with a single electron: electrosurgery and quantum mechanics.Quality of life measurements in epidermolysis bullosa: tools for clinical research and patient care.Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus.Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome).Quality-of-life measurement in blistering diseases.Corticosteroid use in autoimmune blistering diseases.Diffuse melanosis cutis: a systematic review of the literature.The clinical significance of drug interactions between dermatological and psychoactive medications.Multinucleate cell angiohistiocytoma: clinicopathological correlation of 142 cases with insights into etiology and pathogenesis.Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration.A Systematic Review and Critical Evaluation of Reported Pathogenic Sequence Variants in Hidradenitis Suppurativa.Beyond the tip of the iceberg: the role of phosphoinositide 3-kinase/AKT in acne inversa/hidradenitis suppurativa.Tattoo-associated mycobacterial infections: an emerging public health issue.Phenotypic heterogeneity implies heterogeneous pathogenic pathways in hidradenitis suppurativa.Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument.Categorizing immunoflourescence mapping in epidermolysis bullosa with pyloric atresia: Use as a broad prognostic indicator.A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.Corticosteroid use in autoimmune blistering diseases.Disease-specific health related quality of life patient reported outcome measures in Genodermatoses: a systematic review and critical evaluation.Measuring quality of life in epidermolysis bullosa in Mexico: cross-cultural validation of the Hispanic version of the Quality of Life in Epidermolysis Bullosa questionnaire.Health-related quality of life in epidermolysis bullosa: Validation of the Dutch QOLEB questionnaire and assessment in the Dutch population.HLA-B*1502 haplotype screening prior to carbamazepine administration in individuals of south-east Asian ancestry nears cost-effectiveness in preventing severe cutaneous adverse drug reactions.Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 1.Pharmaceutical Benefits Scheme listing of adalimumab for hidradenitis suppurativa: Is hidradenitis suppurativa a life-changing drug or does lifestyle change the drug?Highly Resistant Acrodermatitis Continua of Hallopeau and Pustular Psoriasis.BJD research letters: concise, thought provoking and of general interest.A ski and adventure camp for young patients with severe forms of epidermolysis bullosa.Drug-associated hidradenitis suppurativa: A systematic review of case reports.Lichen amyloidosis involving the scalp.A Retrospective Cohort Study of Melanoma Prevalence Stratified by Body Site in a Regional Australian Population 1994-2017: Site-Specific Protective MechanismsTopical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanismsAutosomal dominant bullous dermolysis of the newborn associated with a heterozygous missense mutation p.G1673R in type VII collagenAdalimumab-induced porokeratosisChlorophyll-induced pseudoporphyria with ongoing photosensitivity after cessation - a case series of four patientsAdopting the orphan: The importance of recognising hidradenitis suppurativa as a systemic auto-inflammatory disease
P50
Q34186834-A73D5168-2602-4B36-9E91-2DFB3798D428Q34487633-C2883451-BCE9-4C74-A701-51D5DA50F186Q34591340-94B0CA71-F81B-46D1-8129-2EDB6168EF6BQ34909685-B1F8EA06-581D-4415-BE51-16C92BA0A8B3Q35010914-73062278-F060-4B88-A860-BB9473693BB7Q37624808-EEC0BD03-A201-47B2-BF82-A9D317BD71FBQ37640804-6B1BE7B9-FC50-460D-AE46-1EBB969A554AQ37933787-F2A320CE-0101-47E1-A9EB-C200815F707CQ37933788-61CA5B04-5F33-4CF2-B3FF-57D7EFB4F59CQ37979353-67796906-D59D-4B4F-9137-AE0C8B3EAED3Q38007620-0C984C9B-2E24-4BEA-A66D-B59234FA3CBAQ38065573-E1ECB20D-9E7E-4F24-8E09-451E47DBC436Q38185684-8F4FACE9-EA52-4D7C-AC4D-16ADDE6EDF44Q38241587-B12D3E75-5278-41E5-B495-6E9E1ED4E5ADQ38764476-7117E993-C30A-4E35-9DB9-D65BB395FFADQ39171115-58403F75-57A2-4C0F-B3FF-C4F213DCACC4Q40745771-1B6CC06F-8163-4F06-B17F-45687D69D51AQ40802012-7917127E-392C-42B2-9152-290A948411F6Q41508421-4B5C8BB2-2046-4296-80E7-0A812AA7DF24Q42630693-16E66486-259F-4FD9-AE52-127795A02351Q42942662-B6DAFB2A-38D9-4689-B378-37424D6CD5EBQ44098231-559A0C19-7AF3-4F9D-836C-50361DDDD5A2Q44595128-76F47AA9-859F-4834-B2F8-AEDA0A5734ABQ47111715-0AFB2111-85C2-4E8F-8139-D27BC79EE3EEQ47720240-75F95395-4474-440B-B04F-4DE720672A7EQ48116214-EE725550-8218-4B50-90B3-D727ACE13A30Q48145273-09E24933-3212-4109-A5F7-155C4A4FE48DQ48198627-1D7C3FE8-08A7-419F-B29B-BEB04E3DE73AQ48333995-1C2162C0-C007-4221-B979-099BB83BA265Q49612268-3079D6F1-A34E-4B28-84BB-7528AE89A4E9Q50020829-750BC366-8312-4B4E-8EBA-41BE519E340EQ51618335-E362D2BD-0EFC-4702-B6EA-B4E020FB6BA6Q52749863-36F8E078-E035-48D1-8B23-B2A847691394Q53799203-5AAAB9D5-7846-4EE8-8CBB-275DB6F35AB0Q58084686-7FC27E69-95AA-4BAB-8A4B-48E030844171Q64084969-D7705B28-64B7-4DAD-8276-3263AACC07DDQ82443773-2626CFB8-9E9C-40C4-AAAA-D23D621D8BDDQ85641743-7DC8AB3C-9E77-4481-B570-94EE2C11FEFCQ87130496-3F890427-F94F-4B6D-AF42-C4E081EB6212Q87175658-54C7DF5D-A5A9-49C5-9581-9C8F51A1C109
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
John Frew
@ast
John Frew
@en
John Frew
@es
John Frew
@nl
John Frew
@sl
type
label
John Frew
@ast
John Frew
@en
John Frew
@es
John Frew
@nl
John Frew
@sl
prefLabel
John Frew
@ast
John Frew
@en
John Frew
@es
John Frew
@nl
John Frew
@sl
P108
P1053
M-8446-2015
P106
P1153
35078289200
P21
P31
P3829
P496
0000-0001-5042-3632